marked.bio

multi-kinase inhibitor · small molecule

cabozantinib

9 active trials across 12 of our biomarkers, targeting MET/VEGFR2 (multi-kinase). Not approved for any biomarker on marked.bio yet.

Also known as XL184, Cabometyx, Cometriq.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
RET fusion or mutation 5 8 Phase 4
BRAF V600E 4 4 Phase 4
NTRK1/2/3 fusion 3 3 Phase 4
KRAS G12C 2 2 Phase 2
KRAS G12D 2 2 Phase 2
ROS1 fusion 2 3 Phase 2
ALK fusion 1 2 Phase 2
EGFR exon 19 deletion / L858R 1 3 Phase 2
HER2 (ERBB2) activating mutation 1 1 Phase 2
MSI-H / dMMR 1 2 Phase 1/2
BRCA1/2 mutation 0 1 –
MET exon 14 skipping 0 2 –

Sponsors

Industry sponsors leading active biomarker-selected trials of cabozantinib.

  1. Kura Oncology 1
  2. Eli Lilly 1

Trials

9 of 17 trials shown

  1. Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study

    Not yet recruiting Phase 4 Fujian Medical University Started 2025Primary completion 2027-12 NCT07010393

    dabrafenib FDA EUtrametinib FDA EUselpercatinibpralsetiniblenvatiniblarotrectinibanlotinibpembrolizumabsintilimabcabozantinibBemosuzumab

    BRAF V600E mutation

    BRAF V600ERET fusion or mutationNTRK1/2/3 fusionThyroid Neoplasms

  2. Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer

    Recruiting Phase 3 ECOG-ACRIN Cancer Research Group Started 2024Primary completion 2030-09 NCT06475989

    cabozantinibdabrafenib FDA EUtrametinib FDA EU

    Patient must have differentiated thyroid cancer (DTC) with BRAF V600E mutation as determined by local testing, including the following subtypes (Note: results …

    BRAF V600ERefractory Differentiated Thyroid Gland Carcinoma

  3. A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer

    Active, not recruiting Phase 3 Eli Lilly Started 2020Primary completion 2023-05 NCT04211337

    selpercatinib FDA EUcabozantinibvandetanib

    A defined/acceptable RET gene alteration identified in a tumor, germline deoxyribonucleic acid (DNA) or blood sample.

    RET fusion or mutationMedullary Thyroid Cancer

  4. A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.

    Recruiting Phase 2 Centre Leon Berard Started 2020Primary completion 2026-10 NCT04116541

    siremadlinribociclibcabozantinibalectinibregorafenibtrametinib FDA EUdabrafenib FDA EUAvapritinib

    …r amplification and/or rearrangement of VEGFR1-3, TIE-2, KIT, RET, RAF1, BRAF (other than V600 mutations), CRAF, HRAS, PDGFR, FGFR1-2, FLT3 and/or CSFR1, and/or amplification of the ligands, an…

    BRAF V600EALK fusionROS1 fusionNTRK1/2/3 fusionMalignant Solid Tumor

  5. Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies

    Recruiting Phase 1/2 Anwaar Saeed Started 2018Primary completion 2028-06 NCT03539822

    cabozantinibdurvalumab FDA EUtremelimumab

    Patients should have known tumor results for microsatellite instability (MSI) or mismatch repair (MMR) proteins.

    MSI-H / dMMRGastric Cancer, Esophageal Adenocarcinoma, Hepatocellular Carcinoma, Colorectal Cancer

  6. Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

    Active, not recruiting Phase 2 National Cancer Institute (NCI) Started 2017Primary completion 2021-06 NCT02867592

    cabozantinib

    …ating mutation, MET translocation, MET exon skipping mutations, activating RET mutations, RET rearrangement, overexpression or activation of AXL)

    RET fusion or mutationAdrenal Cortical Carcinoma, Alveolar Soft Part Sarcoma, Central Nervous System Neoplasm, Childhood Clear Cell Sarcoma of Soft Tissue

  7. Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

    Active, not recruiting Phase 2 National Cancer Institute (NCI) Started 2013Primary completion 2015-08 NCT01708954

    cabozantiniberlotinib FDA EU

    Tumor with a sensitizing mutation in epidermal growth factor receptor (EGFR), defined as follows:

    EGFR exon 19 deletion / L858RKRAS G12CKRAS G12DBRAF V600EHER2 (ERBB2) activating mutationRET fusion or mutationRecurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7

  8. Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity

    Recruiting Phase 2 Memorial Sloan Kettering Cancer Center Started 2012Primary completion 2027-07 NCT01639508

    cabozantinib

    Group C: ROS1 fusion

    ROS1 fusionRET fusion or mutationNTRK1/2/3 fusionNon-Small Cell Lung Cancer

  9. KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

    Recruiting Phase 1 Kura Oncology Started 2023Primary completion 2027-01 NCT06026410

    Darlifarnibcabozantinibadagrasib FDA EU

    …eceived at least 1 prior systemic therapy including available approved SOC treatments for KRAS G12C-mutant locally advanced or metastatic NSCLC, CRC, or PDAC.

    KRAS G12CKRAS G12DSolid Tumors With HRAS Alterations, Non Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC)